• Publications
  • Influence
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
BACKGROUND Chemotherapy combinations that include an alkylating agent and a platinum coordination complex have high response rates in women with advanced ovarian cancer. Such combinations provide
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
TLDR
Bvacizumab has single-agent activity in patients with platinum-resistant EOC or PSC and a higher than expected incidence of GIP was noted in these heavily pretreated patients.
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
TLDR
Age, PS, tumor histology, and residual tumor volume were independent predictors of prognosis in patients with stage III EOC and can be used to identify patients with poor prognosis and to design future tailored randomized clinical trials.
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
TLDR
Compared with standard paclitaxel and carboplatin, addition of a third cytotoxic agent provided no benefit in PFS or OS after optimal or suboptimal cytoreduction as well as survival analyses of groups defined by size of residual disease.
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
TLDR
Neutropenia is the dose-limiting toxicity, and 1.5 mg/m2 is the recommended starting dose of topotecan for both minimally and heavily pretreated patients in future phase II trials, with escalation to 2.0 mg/ m2 if treatment is well tolerated.
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
TLDR
Findings suggest that ultraradical cytoreductive procedures might be targeted for selected patients in whom microscopic residual disease is achievable, and patients with less than 5.0 cm of disease initially and significant disease and/or comorbidities precluding microscopic cytoreduction may be considered for alternative therapeutic options other than primary cytore abduction.
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.
TLDR
To assess the activity of taxol in patients with advanced, progressive, and drug-refractory ovarian cancer and to delineate more clearly the toxicity ofTaxol in this patie...
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
TLDR
The sequence ofTaxol before cisplatin at doses of 135 and 75 mg/m2, respectively, is recommended for phase II/III trials, with escalation of taxol to 170 mg/ m2 if treatment is well tolerated.
...
...